Justin Kim
Stock Analyst at Oppenheimer
(1.49)
# 3,519
Out of 5,090 analysts
38
Total ratings
40%
Success rate
-8.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $26.42 | +89.25% | 5 | Dec 4, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $17 → $16 | $3.74 | +327.81% | 2 | Aug 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $23.63 | +69.28% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $65.67 | +61.41% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $38.78 | +124.34% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $44.90 | -42.09% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $4.70 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $15.62 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $7.59 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $81.68 | -27.77% | 1 | Jul 18, 2022 |
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $26.42
Upside: +89.25%
Zura Bio
Aug 15, 2025
Maintains: Outperform
Price Target: $17 → $16
Current: $3.74
Upside: +327.81%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $23.63
Upside: +69.28%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $65.67
Upside: +61.41%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $38.78
Upside: +124.34%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $44.90
Upside: -42.09%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $4.70
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $15.62
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $7.59
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $81.68
Upside: -27.77%